Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other financing activities (2024 - 2025)

Historic Other financing activities for NewAmsterdam Pharma (NAMS) over the last 2 years, with Q1 2025 value amounting to $1.6 million.

  • NewAmsterdam Pharma's Other financing activities rose 20796.12% to $1.6 million in Q1 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $515000.0 for FY2024, which is N/A changed from last year.
  • Per NewAmsterdam Pharma's latest filing, its Other financing activities stood at $1.6 million for Q1 2025, which was up 20796.12% from $515000.0 recorded in Q1 2024.
  • NewAmsterdam Pharma's Other financing activities' 5-year high stood at $1.6 million during Q1 2025, with a 5-year trough of $515000.0 in Q1 2024.